To date, only one diagnostic test is commercially available for HPV screening and typing. This is a filter hybridisation assay, based on the use of radiolabelled [32P] RNA probes. The sensitivity of this test has not previously been compared with NISH. The aims of this study were twofold: first, to assess the relative diagnostic performance of NISH and the dot-blot hybridisation assay and second, to correlate these data with the cytopathological assessment. To address these issues cervical samples were collected from 122 women undergoing routine gynaecological examination. The samples were tested for the presence of HPV by dot-blot and NISH in separate laboratories and the results evaluated double blind for each cytological diagnostic group. Methods Women (n = 122) undergoing routine gynecological examination were recruited from two sites: Greenville, North Carolina and San Diego, California, USA between March and May 1990. A cervical swab was taken and suspended in medium provided in the dot-blot sample collection kit (ViraPap, ViraType, Digene Diagnostics, Inc, Silver Spring, Maryland, USA). A cervical smear was taken at the same time from each patient and fixed immediately in the standard way. NISH was performed on the smear while the suspended cells, from the swab, were assayed for the presence of HPV and HPV type by the dot-blot assay. After NISH was performed, smears were counterstained with haematoxylin and assessed both cytopathologically and for the presence of NISH signal." Cytopathology, NISH (Oxford University) and dot-blot hybridisation (Roche Biomedical Laboratories) were performed double blind and the results compared.
Infection with certain types of human papillomavirus (HPV 16, 18,  4`'7 In situ hybridisation has the advantage over other methods in that it permits unequivocal localisation of HPV genomes to epithelial cells and thereby obviates the risk of false positive results due to laboratory or clinical contamination.
To date, only one diagnostic test is commercially available for HPV screening and typing. This is a filter hybridisation assay, based on the use of radiolabelled [32P] RNA probes. The sensitivity of this test has not previously been compared with NISH. The aims of this study were twofold: first, to assess the relative diagnostic performance of NISH and the dot-blot hybridisation assay and second, to correlate these data with the cytopathological assessment. To address these issues cervical samples were collected from 122 women undergoing routine gynaecological examination. The samples were tested for the presence of HPV by dot-blot and NISH in separate laboratories and the results evaluated double blind for each cytological diagnostic group.
Methods
Women (n = 122) undergoing routine gynecological examination were recruited from two sites: Greenville, North Carolina and San Diego, California, USA between March and May 1990. A cervical swab was taken and suspended in medium provided in the dot-blot sample collection kit (ViraPap, ViraType, Digene Diagnostics, Inc, Silver Spring, Maryland, USA). A cervical smear was taken at the same time from each patient and fixed immediately in the standard way. NISH was performed on the smear while the suspended cells, from the swab, were assayed for the presence of HPV and HPV type by the dot-blot assay. After NISH was performed, smears were counterstained with haematoxylin and assessed both cytopathologically and for the presence of NISH signal." Cytopathology, NISH (Oxford University) and dot-blot hybridisation (Roche Biomedical Laboratories) were performed double blind and the results compared.
DOT-BLOT FILTER HYBRIDISATION
Cell disruption, denaturation, and immobilisation of DNA on to nylon filters, hybridisation, and detection were carried out according to the manufacturer's instructions. Briefly, the procedure was as follows: specimens were incubated with sample preparation reagent at 37°C for one hour to complete cell lysis. DNA denaturation was achieved by incubation in 866 HPV detection by ViraPap and NISH alakaline solution. The DNA was bound to a nylon filter under vacuum and the membrane transferred to a reaction tray, covered with prehybridisation buffer and incubated at 60'C for 30 minutes. The hybridisation mix contained a cocktail of 32P-RNA transcripts to HPV types 6, 11, 16, 18, 31, 33 and 35. The membrane was hybridised at 60'C for two hours and nonspecifically bound probe was removed by RNase treatment and low and high stringency post-hybridisation washes. Autoradiography was then carried out at -70'C for 48-72 hours and the presence of HPV DNA in the sample was determined by the presence of an autoradiographic signal. Samples positive by dot-blot (ViraPap) were further HPV typed by ViraType assay, which differs only in that three replicate membranes are hybridised with separate cocktails of complementary radiolabelled probes (HPV 6/11; 16/18 and 31/33/35).
NISH ON CERVICAL SMEARS
In situ hybridisation was performed on routine cervical smears, as previously described."
Briefly, smears were washed in freshly prepared methanol/acetic acid (3:1 = v/v), fixed in 4% paraformaldehyde (w/v) in PBS (PBS = 10 mM phosphate, 150 mM NaCl, pH 7.4), endogenous peroxidase activity blocked in peroxide/azide and nucleic acids unmasked using 1 ,ug/ml proteinase K. Smears were then postfixed in paraformaldehyde, washed in PBS and air dried. A cocktail of HPV 6, 11, 16, 18 , 31 and 33 probes (2 ng/,ul each) labelled with digoxigenin by nick translation'8 was added to the hybridisation mix containing 50% (v/v) formamide, 5% (w/v) dextran sulphate, 2 x SSC (1 x SSC = 0-15 M ¢ sodium chloride, 0-015 M sodium citrate), 50 mM TRIS-HCI, pH 7-2, 5 mM EDTA, 0 1% (w/v) sodium pyrophosphate 0-2% (w/v) polyvinylpyrollidine 400 000 molecular weight, 0-2% (w/v) Ficoll 400 000 molecular weight and 200 ng/pul sheared human DNA. Target DNA and probes were denatured simultaneously at 95'C for 15 minutes and hybridised at 42°C for two hours.'8 After hybridisation, smears were washed twice in 4 x SSC and soaked in blocking agent (TBT) comprising 50 mM TRIS-HCI (pH 7 2). 100 mM NaCl, 1 mM MgCl2 (TBS) containing 3% (w/v) bovine serum albumin, 0 05% (v/v) Triton X-100. Smears were sequentially incubated in monoclonal anti-digoxin (Sigma UK), biotinylated rabbitanti mouse F(ab')2 fragment (Dako UK), and avidin peroxidase conjugate in TBT containing 5% (w/v) non-fat milk (Cadbury UK).`' A red NISH signal was developed by incubation in 3-amino-9-ethylcarbazole, H202 (Zymed USA) for 10 minutes. The reaction was stopped by washing in water smears counterstained progressively with haematoxylin for 10-15 seconds and mounted in glycerol jelly. 20 .~~~~~~~~~~~~~~~- I.
-------- In each dot-blot assay the controls included by the manufacturers gave the expected autoradiographic signal. Controls in all NISH experiments included CaSki cell smears (which contain integrated HPV 1622); and cytologically normal cervical smears (from a separate cohort). These were hybridised with HPV 16 and total human DNA, respectively.23 Multiple nuclear signals were obtained in CaSki cells20 and total human DNA labelled every nucleus in control smears.
Discussion
Women infected with specific HPV types may have an additional risk of developing cervical neoplasia. Microscopic evidence of HPV infection has been associated with a 16-fold increase in the risk of developing CIN 3 in six years.24 Cytology, however, detects only cytopathic viral infection, while latent infection can be demonstrated only by hybridisation techniques.2 Consequently, many groups have analysed the frequency of infection of normal and abnormal cervical cells and tissues by HPV using filter hybridisation methods5`8 and more recently by PCR. 14-17 However, these methods detect not only viral genomes derived from infected cells, but may also detect extracellular HPV originating from cervico-vaginal secretions. In addition, the clinical importance of detecting as few as 10 HPV molecules per sample using PCR remains to be established. 16 Only in situ hybridisation localises HPV sequences to cells which may subsequently be cytopathologically assessed.
The sensitivity of NISH for the detection of HPV DNA in cultured cells was previously estimated to be 2-5-12 copies.'9 This methodology was applied to routine cervical smears and adapted to overcome problems related to the presence of a variable amount of mucin or to the frequent contamination with bacteria, fingi, and protozoa." This technique can be performed using basic laboratory equipment within one working day and therefore has a potential role in routine cervical screening.
At present, only one dot-blot diagnostic test is commercially available for HPV detection in exfoliated cervical cells. This is a filter hybrid- analysis.'6 '1 Thus the apparently high prevalence of HPV sequences in patients with apparently normal cervical smears is probably due in part to sampling error between the Papinacolaou stained smear and the sample used for molecular analysis, and in part to the failure of screening cytopathology to detect minor nuclear changes associated with HPV infection. The management of women with human papillomavirus DNA without cytological evidence of a lesion therefore presents clinical difficulties. Such patients are at increased risk of developing preneoplastic and invasive lesions and close follow up screening is required. 26 In conclusion, we have shown that NISH on cytological smears has potentially greater diagnostic sensitivity than a standardised dot-blot assay for detecting HPV infection. This NISH method is also suitable for a large scale screening programme. It does not require any change in the Papinacolaou smear sampling procedure, being performed on a second specimen collected in the same way. Modification of the procedure has allowed low and high risk types to be differentiated on individual routine cervical smears.'0 Another advantage is that the same cytotechnician can interpret both the molecular and cytological result. However, to assess the relation between HPV and cervical cancer, data are required on the prevalence of the virus, together with the natural history of the associated lesions on follow up. As a tool to answer these questions, NISH may be used as a sensitive, specific and routinely applicable screening technique.
